

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1 Name and Address of Company**

HYTN Innovations Inc. (the “Company”)  
12 East 4th Avenue  
Vancouver, BC  
Canada V5T 1E8

**Item 2 Date of Material Change**

March 4, 2024

**Item 3 News Release**

The Company disseminated a news release announcing the material change described herein through the news dissemination service of Globe Newswire on March 4, 2024, and a copy was subsequently filed on SEDAR+.

**Item 4 Summary of Material Change**

The Company announced the successful completion of a Good Manufacturing Practices (“GMP”) audit by Australia's Therapeutic Goods Administration (“TGA”) at its Kelowna facility. The positive outcome of the audit has set the stage for the subsequent issuance of formal GMP certification allowing the Company to access international medical markets.

**Item 5 Full Description of Material Change**

**5.1 Full Description of Material Change**

The Company announced the successful completion of a GMP audit by Australia's TGA at its Kelowna facility. The positive outcome of the audit has set the stage for the subsequent issuance of formal GMP certification allowing the Company to access international medical markets.

The successful GMP audit, in coordination with Australia's Promethean Biopharma, confirms the Company as one of the few companies in Canada qualified to package and label finished cannabis goods in accordance with GMP regulations for international medical markets; facilitating the supply of high-quality medical cannabis products to international clients and enabling collaboration with global firms.

The GMP audit conducted by the TGA was performed in accordance with the standards of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (“PIC/S”). The successful audit is a key achievement for the Company, demonstrating the robustness of the company’s infrastructure and the effectiveness of its processes. Once issued, GMP certification under the PIC/S framework allows the Company to engage with international medical markets that recognize the PIC/S standard, through established reciprocal agreements. This milestone aligns with the growth of robust international cannabis markets which require GMP certification to effectively commercialize.

**5.2 Disclosure for Restructuring Transactions**

Not applicable.

**Item 6 Reliance on Subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7 Omitted Information**

Not applicable.

**Item 8 Executive Officer**

For further information, please contact Elliot McKerr, Chief Executive Officer of 866-590-9289 or via email to [invest@hytn.life](mailto:invest@hytn.life).

**Item 9 Date of Report**

March 12, 2024